Immune-related adverse events: what we’ve learned and where we’re heading
| Autor: | Michael Dougan, Donna E. Leet, Yousef R. Badran |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Heading (navigation)
animal diseases chemical and pharmacologic phenomena Article Vedolizumab Immune system Neoplasms medicine Animals Humans Pharmacology (medical) Adverse effect Immune Checkpoint Inhibitors business.industry biochemical phenomena metabolism and nutrition humanities Infliximab Oncology CTLA-4 Immunology Monoclonal bacteria Tumor necrosis factor alpha Immunotherapy business medicine.drug |
| Zdroj: | Expert Rev Anticancer Ther |
| ISSN: | 1744-8328 1473-7140 |
| Popis: | Over the past decade, the treatment of both solid and hematologic malignancies has been revolutionized by therapies that harness the immune response. Immune-checkpoint inhibitors (ICIs), monoclonal... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|